Targeting the constitutively active BRAF V600 mutant protein, in association with MEKi to prevent the paradoxical reactivation of the BRAF pathway, represents one of the most effective therapeutic strategies in the management of this potentially lethal skin cancer. This evidence concerns the gene BRAF and skin neoplasm.